OFIXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 23
Orthofix Medical Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$9.59+0.21 (+2.24%)
Close on Oct 19, 2026
- Market cap
- $392.29M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
68.8%−6.1 pts over 5 years
Operating margin
-9.9%−8.4 pts over 5 years
Net margin
-11.2%−11.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +2.9% | +21.3% | +15.1% | +7.6% | |
| Gross profit | +3.7% | +18.8% | +13.2% | +6.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 1.1% | 0.7% | -19.3% | |
| Return on assets | 0.8% | 0.5% | -10.6% | |
| Current ratio | 2.33 | 2.60 | 2.45 | |
| Debt to equity | – | – | 0.35 | |
| Net debt to EBITDA | – | – | -18.35× | |
| Inventory turnover | 1.5× | 1.2× | 1.4× | |
| Capex to revenue | 4.0% | 3.8% | 4.2% | |
| Diluted shares | 18M | 19M | 40M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Orthofix Medical generated $134.90M from operations and spent $172.50M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$134.90M
Used
$172.50M
Capital expenditure$172.50M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-11.2%
×Asset turnover0.94×
×Equity multiplier1.83×
=Return on equity, FY2025-19.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -11.2% | 0.94× | 1.83× | -19.3% |
| FY2024 | -15.8% | 0.88× | 1.65× | -22.9% |
| FY2023 | -20.3% | 1.08× | 1.48× | -32.4% |
| FY2022 | -4.3% | 0.99× | 1.39× | -5.9% |
| FY2021 | -8.3% | 0.93× | 1.44× | -11.1% |
| FY2020 | 0.6% | 0.80× | 1.49× | 0.7% |
| FY2019 | -6.2% | 0.96× | 1.45× | -8.6% |
| FY2018 | 3.0% | 1.04× | 1.38× | 4.4% |
| FY2017 | 1.4% | 1.12× | 1.39× | 2.2% |
| FY2016 | 0.7% | 1.06× | 1.39× | 1.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$92.19M
- Cash generatingOperating cash flow above zero$33.35M
- Return on assets improvedROA up on the prior year-13.6% → -10.3%
- Earnings backed by cashOperating cash flow above net income$33.35M vs -$92.19M
- Less leverageLong-term debt to assets fell17.6% → 18.5%
- Better liquidityCurrent ratio rose2.57 → 2.45
- No dilutionShare count did not rise38M → 40M
- Gross margin improvedGross margin up on the prior year68.28% → 68.83%
- More efficientAsset turnover rose0.86 → 0.92